Clinical trial

Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

NCT01576029

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-08-01

PhasePHASE2

Study timeline

Study start (unknown)2012-08-01Date precision: month

Registry last updated2013-12-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostatic Neoplasmsunresolved

Interventions

CABAZITAXEL (XRP6258)DRUG

DOCETAXEL (XRP6976)DRUG

Sponsors & collaborators

Sanofilead sponsor

Mapped research locations

Rio de JaneiroBrazil2 São PauloBrazil1 Porto AlegreBrazil1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01576029 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.